FINWIRES · TerminalLIVE
FINWIRES

$HQY

8 stories mentioning HQYUpdated 15d ago

Every FINWIRES story that references HQY, newest first.

What's the latest news on HQY?

Wire

HealthEquity Catalysts Intact After Q2 Beat, RBC Says

HealthEquity (HQY) delivered better-than-expected Q2 results, keeping its margin runway and fiscal 2028 catalysts intact, RBC Capital Markets said in a Thursday note.The report pointed to a record 48% adjusted EBITDA margin, driven by continued AI-enabled service cost reductions.The note said a slower HSA cash-balance growth reflects a deliberate strategy toward higher-value investment accounts andMarketplace engagement. It said the strategy is "accretive" rather than a degradation of the model."Marketplace and Bronze plan enrollment represent emerging catalysts," the report said. The firm's primary offerings are based on the administration of health savings accounts and other consumer-directed benefits.RBC kept its outperform rating and a price target of $108.Price: $96.20, Change: $+2.81, Percent Change: +3.01%

$HQY
Insider Trading

Healthequity Insider Sold Shares Worth $798,373, According to a Recent SEC Filing

Adrian T Dillon, Director, on August 25, 2026, sold 7,632 shares in Healthequity (HQY) for $798,373. Following the Form 4 filing with the SEC, Dillon has control over a total of 62,395 common shares of the company, with 62,395 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1428336/000116340226000004/xslF345X05/form4-08272026_090857.xml

$HQY
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks fell late Thursday afternoon, with the NYSE Healthcare Index down 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1%.The iShares Biotechnology ETF (IBB) was down 0.1%.In corporate news, Moderna (MRNA) shares dropped 5% after the firm said it plans to offer $2 billion worth of convertible senior notes due 2032 in a private placement.HealthEquity (HQY) shares fell past 10% after the company posted fiscal Q2 results.Novo Nordisk (NVO) said China's National Medical Products Administration has accepted its marketing application for the oral version of its weight-loss drug Wegovy, Reuters reported. Shares were down 2%.NeoGenomics (NEO) shares jumped past 7% after the company said its RaDaR ST molecular residual disease assay received expanded Medicare coverage to include immunotherapy response monitoring for patients with late-stage solid tumors.

$HQY$MRNA$NEO$NVO
Sectors

Sector Update: Healthcare Stocks Softer in Afternoon Trading

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) was fractionally lower.In corporate news, Moderna (MRNA) shares fell 4.5% after it said Thursday it plans to offer $2 billion worth of convertible senior notes due 2032 in a private placement.HealthEquity (HQY) shares fell past 11% after the company posted fiscal Q2 results.Novo Nordisk (NVO) said Thursday that China's National Medical Products Administration has accepted its marketing application for the oral version of its weight-loss drug Wegovy, Reuters reported. Reuters said the regulator's acceptance of the application is not approval to sell Novo Nordisk's once-daily semaglutide tablets to patients in China, but rather that officials have determined that the application is complete and may enter formal review. Novo shares were down 2.1%.

$HQY$MRNA$NVO
Wire

Update: HealthEquity Shares Fall After Fiscal Q2 Results

(Updates with share price movement in the headline and first paragraph.)HealthEquity (HQY) shares fell nearly 14% in early Thursday trading after the company posted fiscal Q2 results.The company reported fiscal Q2 adjusted earnings of $1.24 per diluted share, compared with $1.08 a year earlier.Analysts polled by FactSet expected $1.19.Total revenue for the three months ended July 31 was $350.7 million, compared with $325.8 million a year earlier.Analysts surveyed by FactSet expected $349.2 million.The company said it now expects fiscal 2027 revenue of $1.411 billion to $1.421 billion, versus a prior outlook of $1.410 billion to $1.420 billion. Analysts expect $1.42 billion.Fiscal 2027 adjusted net income per diluted share is estimated to be $4.66 to $4.73, unchanged from before. Analysts expect $4.72.Price: $89.84, Change: $-14.59, Percent Change: -13.97%

$HQY
Sectors

Sector Update: Healthcare Stocks Decline Pre-Bell Thursday

Healthcare stocks were declining pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.6% lower and the iShares Biotechnology ETF (IBB) down 0.5%.Novo Nordisk (NVO) said China's National Medical Products Administration has accepted its marketing application for the oral version of its weight-loss drug Wegovy, Reuters reported. Novo Nordisk stock was down more than 2% premarket.Moderna (MRNA) shares were down nearly 5% amid the company's plans to offer $2 billion worth of convertible senior notes due 2032 in a private placement.HealthEquity (HQY) stock was down more than 5% even after the company reported higher fiscal Q2 adjusted earnings and revenue.

$HQY$IBB$MRNA$NVO$XLV
Insider Trading

Healthequity Insider Sold Shares Worth $298,490, According to a Recent SEC Filing

Michael Henry Fiore, Executive Vice President, Chief Commercial Officer, on May 29, 2026, sold 3,142 shares in Healthequity (HQY) for $298,490. Following the Form 4 filing with the SEC, Fiore has control over a total of 59,113 common shares of the company, with 59,113 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1428336/000201611626000012/xslF345X05/form4-06022026_090621.xml

$HQY
Wire

HealthEquity Posts Q1 Beat-and-Raise on Strong HSA Growth, AI-Driven Efficiency, RBC Says

HealthEquity (HQY) delivered a strong start to fiscal 2027 with a Q1 earnings beat and raise outlook, supported by above-market health savings account growth and meaningful operational leverage, RBC Capital said in a Friday note.The analysts noted that HSA accounts rose 8% year over year, outpacing broader market growth, with the company reporting its strongest enterprise sales pipeline in years and benefiting from expanded offerings and improved digital engagement.RBC highlighted meaningful operational leverage driven by AI deployment and service optimization, with service costs declining despite higher account volumes as automation reduced manual workloads and improved efficiency across servicing functions, according to the report.The investment firm also pointed to potential long-term regulatory tailwinds that could expand the HSA addressable market, though it cautioned that near-term labor market softness could moderate account growth and balance expansion in future periods.RBC raised its price target on the stock to $108 from $100 while maintaining its outperform rating.Shares of HealthEquity were down nearly 1% in Friday trading.Price: $89.72, Change: $-0.80, Percent Change: -0.88%

$HQY

Track with the FINWIRES app suite

FolioX
FolioX
Track HQY in your portfolio
WheelAI
WheelAI
Analyze HQY options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HQY